PrecisionLife has published data demonstrating the potential opportunities for biopharma companies to develop new treatments for millions of patients with unmet medical needs by systematically repositioning hundreds of patented drugs into new indications

The peer-reviewed study, published in a Cell Patterns special edition focusing on artificial intelligence drug discovery, highlighted 477 potential repositioning opportunities in over 35 secondary disease indications across the development and marketed drug pipelines of 177 companies, based on deep analysis of shared mechanisms and patient stratification biomarkers in the secondary indications.

Pharmaceutical companies are "sitting on a gold mine" in their patented drug portfolios, with the potential to bring new treatments to market faster and cheaper across more than 35 chronic diseases, according to PrecisionLife.

"Combinatorial analytics and high-resolution patient stratification have the potential to enhance the rate of innovation across the drug discovery industry. This can reduce drug development risk and increase revenue at the same time as offering patients the hope of rapid access to new, more personalized therapeutic options for a wide range of underserved diseases and patient subgroups," said Steve Gardner, PhD, CEO of PrecisionLife and co-author of the paper.